Background: Lung cancer remains as the leading cause of cancer-related deaths worldwide, with non-small cell carcinoma (NSCLC) being the most frequent histology (85%). Therapies that target activating EGFR mutations are NSCLC first-line treatments that improve patient life expectancy and quality of life. However, despite the current availability of novel TKI drugs in Chile and other Latin-Americans countries, little is known about the molecular epidemiology of EGFR mutations in the region. In particular, Latin American patients are still largely under-represented in genomics databases or clinical trials for this disease. We are presenting the results of a large NGS-based screening of the NSCLC EGFR mutations in Chilean patients. The study is aimed at describing the prevalence of specific somatic actionable mutations, within this population and correlated data with relevant clinical and tumor aspects such as gender, age, specific histology, smoking habits, progression stage and co-occurrencewith KRAS mutations and other mutations. Method: Non-small cell lung cancer FFPE samples from 821 subjects, part of the non-interventional clinical study NIRVANA (NCT03220230), were sequenced using Oncomine Focus Assay (Thermo Fisher Scientific), which covers the most frequent and actionable EGFR mutations through nine amplicons of w100bp, spanning eight exons, to call variant at an expected mean coverage of 1000x. Variants called by the Ion Reporter Server were manually filtered by allele frequency >¼ 0.05 and at least 10 supporting reads, discarding synonymous substitutions and homozygous reference genotypes. Variants were annotated against COSMIC, dbSNP and ExAC databases to classify them in known or novel variants. Functional impact algorithms SIFT and PolyPhen were used. Clinical information was gathered on a GCP-compliant setup and monitored 100% on-site. Prevalence is reported within 95% CI, and associations with clinical characteristics are evaluated by Chi-Squared test or ANOVA, as appropriate (p<0.05). Results: We found that 214 out of 821 subjects, or 26.06% (95% CI: 23.15% to 29.14%) of the studied population, harbor an EGFR mutation. Among known variants, exon 19 E746_A750 deletion (COSM13243) and exon 18 A698T (COSM41905) were the most abundant variations. Non-smokers and under 45 years old subjects were more likely to have a relevant EGFR mutation (p<0.01), in agreement with the literature. Gender did not correlate significantly as a predictor of EGFR mutations (p>0.15) in the cohort analyzed. Background: EGFR mutation status is crucial to improving therapeutic results in advanced NSCLC, due to the development of highly effective EGFR-TKIs. Recent local data suggest that EGFR mutation frequency is lower in Brazil (22%-33%) than in Asia and higher than in North America and Europe. We intended to describe EGFR uncommon mutation frequency found in a large national-wide Brazilian population database. Method: This retrospective analysis evaluated a database composed of samples collected between January and August 2017, from all Brazilian regions. Tumor tissue samples of patients with advanced NSCLC EGFR-TKI naïve were submitted, at discretion of attending physicians, for EGFR mutation testing. EGFR exons 18 to 21 were analyzed by cobas®, NGS, or other non-specified test. Results: 1,688 tests were included. From all positive tests (n¼429; 25.4%), exon 19 deletion was the most frequent (51.5%), followed by L858R (27.3%), and exon 20 insertion (8.4%). Uncommon mutations in each of these exons were found in a much lower frequency as shown in the Table 1 , with the point mutation S768I (2.10%) in exon 20 being the most common, followed by G719X (1.86%) in exon 18, and L861Q (1.63%) in exon 21. Smoking status data was not available and was not included in this analysis. Conclusion: Our findings show a considerable 12.8% rate of uncommon EGFR mutations in the presently studied patients. Its impact on response to EGFR-TKIs must be better addressed in real-world studies. Table1 e Frequency of uncommon EGFR mutations.
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